|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...910111213141516171819...4950» |
- Enrollment closed, Trial primary completion date, IO biomarker: Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Apr 30, 2015
P=N/A, N=629, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Sep 2015
- | NN1213 / Novo Nordisk
Trial completion: OPTIMA: CSP #512 - Options in Management With Anti-Retrovirals (clinicaltrials.gov) - Apr 29, 2015
P=N/A, N=368, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Sep 2015 No longer recruiting --> Completed
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment open: Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents (clinicaltrials.gov) - Apr 28, 2015
P2, N=150, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion, Trial primary completion date: Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test (clinicaltrials.gov) - Apr 25, 2015
P=N/A, N=1649, Completed, Sponsor: MedMira Laboratories Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015
- Trial completion, Enrollment change, HEOR: Medical Marijuana Use in HIV+ Patients: Probability Survey (clinicaltrials.gov) - Apr 23, 2015
P=N/A, N=218, Completed, Sponsor: Wayne State University
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015 Recruiting --> Completed | N=300 --> 218
- | efavirenz / Generic mfg., abacavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Enrollment change: NEVEREST-III: Treatment Options for Protease Inhibitor-exposed Children (clinicaltrials.gov) - Apr 23, 2015
P3, N=300, Completed, Sponsor: Columbia University
Recruiting --> Completed | N=300 --> 218 Active, not recruiting --> Completed | N=400 --> 300
- Trial primary completion date: Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM) (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=960, Recruiting, Sponsor: Medical College of Wisconsin
Active, not recruiting --> Completed | N=400 --> 300 Trial primary completion date: Jul 2015 --> Jul 2016
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) - Apr 20, 2015
P=N/A, N=400, Recruiting, Sponsor: ViiV Healthcare
Trial primary completion date: Jul 2015 --> Jul 2016 Not yet recruiting --> Recruiting
- ||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed, Trial primary completion date: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Apr 20, 2015
P3, N=538, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2015
- Trial primary completion date: OCTIHIV: Revealing Increased Axonal Loss in Treated HIV Patients (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=150, Recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2015 Trial primary completion date: Feb 2015 --> Aug 2015
- |||| darunavir/ritonavir / Generic mfg.
Trial primary completion date, Combination therapy, Monotherapy: A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (clinicaltrials.gov) - Apr 19, 2015
P3, N=273, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Trial primary completion date: Feb 2015 --> Aug 2015 Trial primary completion date: Jan 2015 --> Jun 2014
- |||| Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial completion, Combination therapy: Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection (clinicaltrials.gov) - Apr 17, 2015
P2, N=192, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Jan 2015 --> Jun 2014 Active, not recruiting --> Completed
- | tenofovir vaginal gel (GS-1278 gel) / Gilead, CONRAD
Trial completion, Enrollment change: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection (clinicaltrials.gov) - Apr 16, 2015
P3, N=2059, Completed, Sponsor: CONRAD
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=2900 --> 2059
- Enrollment change: DAART+: Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India (clinicaltrials.gov) - Apr 15, 2015
P2/3, N=0, Withdrawn, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | N=2900 --> 2059 N=100 --> 0
- Trial primary completion date: HandiVIH: Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=1700, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
N=100 --> 0 Trial primary completion date: Mar 2016 --> Dec 2015
- Trial primary completion date: Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=200, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial primary completion date: Mar 2016 --> Dec 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- GSK2838232 / GSK
Trial suspension: A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (clinicaltrials.gov) - Apr 14, 2015
P1, N=20, Suspended, Sponsor: GlaxoSmithKline
Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Suspended
- GSK2838232 / GSK
Trial suspension: A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (clinicaltrials.gov) - Apr 14, 2015
P1, N=40, Suspended, Sponsor: GlaxoSmithKline
Active, not recruiting --> Suspended Recruiting --> Suspended
- || Trial primary completion date: HCV/HIV Coinfection: Antiviral Therapy and Fibrosis (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=1250, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Suspended Trial primary completion date: Oct 2014 --> Oct 2018
- Isentress (raltegravir) / Merck (MSD)
Trial withdrawal, Trial primary completion date: RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) - Apr 14, 2015
P3, N=0, Withdrawn, Sponsor: McGill University Health Center
Trial primary completion date: Oct 2014 --> Oct 2018 Terminated --> Withdrawn | Trial primary completion date: Dec 2012 --> Aug 2011
- | Ogsiveo (nirogacestat) / SpringWorks Therap
Trial initiation date, Trial primary completion date: Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma (clinicaltrials.gov) - Apr 14, 2015
P2, N=20, Not yet recruiting, Sponsor: AIDS Malignancy Clinical Trials Consortium
Terminated --> Withdrawn | Trial primary completion date: Dec 2012 --> Aug 2011 Initiation date: Jun 2014 --> Jul 2015 | Trial primary completion date: Aug 2015 --> Jul 2017
- Enrollment closed: A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV (clinicaltrials.gov) - Apr 14, 2015
P2, N=750, Active, not recruiting, Sponsor: Nova Southeastern University
Initiation date: Jun 2014 --> Jul 2015 | Trial primary completion date: Aug 2015 --> Jul 2017 Recruiting --> Active, not recruiting
- | Trial completion: An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users (clinicaltrials.gov) - Apr 14, 2015
P3, N=1260, Completed, Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: A Mixed-Methods Approach to Understanding Factors Associated With Cervical Cancer Screening Utilization Among Low-Income, HIV-Positive Women (clinicaltrials.gov) - Apr 13, 2015
P=N/A, N=188, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=250 --> 188 | Initiation date: Oct 2012 --> Jul 2012 | Trial primary completion date: Sep 2015 --> Apr 2015
- | NN1213 / Novo Nordisk
Trial completion: Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants (clinicaltrials.gov) - Apr 13, 2015
P2, N=120, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | N=250 --> 188 | Initiation date: Oct 2012 --> Jul 2012 | Trial primary completion date: Sep 2015 --> Apr 2015 Active, not recruiting --> Completed
- Enrollment open, Trial primary completion date: TLCIDU Kenya: Testing and Linkage to Care for Injecting Drug Users in Kenya (clinicaltrials.gov) - Apr 8, 2015
P=N/A, N=4500, Recruiting, Sponsor: New York University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2015
- | ViraferonPeg (peginterferon-?-2b) / Merck (MSD), Isentress (raltegravir) / Merck (MSD)
Trial completion, Trial primary completion date: Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds (clinicaltrials.gov) - Apr 8, 2015
P4, N=40, Completed, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2015 Recruiting --> Completed | Trial primary completion date: Aug 2013 --> Apr 2015
- |||| abacavir/lamivudine/zidovudine / Generic mfg.
Trial completion: Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure (clinicaltrials.gov) - Apr 6, 2015
P4, N=100, Completed, Sponsor: ViiV Healthcare
Recruiting --> Completed | Trial primary completion date: Aug 2013 --> Apr 2015 No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Improving HIV Screening With Nurse-Based Rapid Testing/Streamlined Counseling (clinicaltrials.gov) - Apr 5, 2015
P=N/A, N=251, Completed, Sponsor: Department of Veterans Affairs
No longer recruiting --> Completed No longer recruiting --> Completed
- Trial completion, Trial primary completion date: Effectiveness of a Cell Phone-Based Program for Abstinence and HIV Risk Prevention (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=103, Completed, Sponsor: University of Colorado, Denver
No longer recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2009 --> May 2013
- GTU-multi-HIV B clade DNA vaccine / ValiRx
Enrollment closed, Trial primary completion date: Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers (clinicaltrials.gov) - Apr 2, 2015
P1/2, N=92, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2009 --> May 2013 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015
- Enrollment change: A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides (clinicaltrials.gov) - Apr 1, 2015
P0, N=12, Completed, Sponsor: Johns Hopkins University
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015 N=10 --> 12
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) (clinicaltrials.gov) - Apr 1, 2015
P4, N=240, Completed, Sponsor: Hospital Clinic of Barcelona
N=10 --> 12 Recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (clinicaltrials.gov) - Apr 1, 2015
P4, N=240, Completed, Sponsor: Hospital Clinic of Barcelona
Recruiting --> Completed Recruiting --> Completed
- ||||||| Trial completion, Enrollment change: ECHO: Enhancing Communication and HIV Outcomes (clinicaltrials.gov) - Apr 1, 2015
P3, N=186, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed Active, not recruiting --> Completed | N=240 --> 186
- Trial completion, Enrollment change, Trial primary completion date: Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users (clinicaltrials.gov) - Apr 1, 2015
P=N/A, N=413, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed | N=240 --> 186 Active, not recruiting --> Completed | N=520 --> 413 | Trial primary completion date: Feb 2010 --> Mar 2011
- Enrollment closed, Trial primary completion date: Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002 (clinicaltrials.gov) - Mar 31, 2015
P2, N=168, Active, not recruiting, Sponsor: Barbara Ensoli, MD
Active, not recruiting --> Completed | N=520 --> 413 | Trial primary completion date: Feb 2010 --> Mar 2011 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Sep 2018
- Enrollment closed, Trial primary completion date: Progress Adult Study (clinicaltrials.gov) - Mar 31, 2015
P=N/A, N=5600, Active, not recruiting, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Sep 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2020
- Trial completion, Enrollment change, Trial primary completion date: Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment (clinicaltrials.gov) - Mar 31, 2015
P4, N=109, Completed, Sponsor: International Medical Center of Japan
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2020 Recruiting --> Completed | N=240 --> 109 | Trial primary completion date: Mar 2011 --> Feb 2012
- | Trial completion, Trial primary completion date: Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment (clinicaltrials.gov) - Mar 31, 2015
P3, N=71, Completed, Sponsor: International Medical Center of Japan
Recruiting --> Completed | N=240 --> 109 | Trial primary completion date: Mar 2011 --> Feb 2012 Active, not recruiting --> Completed | Trial primary completion date: Jul 2008 --> Sep 2009
- || Enrollment closed: Progress Pediatric Study (clinicaltrials.gov) - Mar 27, 2015
P=N/A, N=840, Active, not recruiting, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Active, not recruiting --> Completed | Trial primary completion date: Jul 2008 --> Sep 2009 Recruiting --> Active, not recruiting
- Invirase (saquinavir) / Roche
Enrollment change: Bioequivalence Study of Generic GPO Saquinavir and Norvir (clinicaltrials.gov) - Mar 26, 2015
P1/2, N=0, Withdrawn, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Recruiting --> Active, not recruiting N=30 --> 0
- ||||| Edurant (rilpivirine) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J, Intelence (etravirine) / J&J
Enrollment change, Trial primary completion date: A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women (clinicaltrials.gov) - Mar 25, 2015
P3, N=80, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
N=30 --> 0 N=50 --> 80 | Trial primary completion date: Aug 2016 --> May 2017
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial completion: Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Mar 25, 2015
P1, N=96, Completed, Sponsor: HIV Vaccine Trials Network
N=50 --> 80 | Trial primary completion date: Aug 2016 --> May 2017 Active, not recruiting --> Completed
- atorvastatin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia (clinicaltrials.gov) - Mar 25, 2015
P1/2, N=28, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 28 | Trial primary completion date: Apr 2014 --> Dec 2014
- Trial completion, Discordant: EPIC: Enhanced Prevention in Couples: Feasibility Study #2 (clinicaltrials.gov) - Mar 24, 2015
P=N/A, N=191, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed | N=40 --> 28 | Trial primary completion date: Apr 2014 --> Dec 2014 Active, not recruiting --> Completed
- Trial completion, Discordant: EPIC: Enhanced HIV Prevention in Couples: Feasibility Study #1 (clinicaltrials.gov) - Mar 24, 2015
P=N/A, N=230, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Vocabria (cabotegravir oral) / ViiV Healthcare
Enrollment open: Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir (clinicaltrials.gov) - Mar 23, 2015
P3, N=36, Recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change: Effects of Maternal Anti-HIV Treatment on Infants Born to HIV-Infected Women (clinicaltrials.gov) - Mar 18, 2015
P=N/A, N=236, Completed, Sponsor: AIDS Clinical Trials Group
Not yet recruiting --> Recruiting N=410 --> 236
- Trial completion: Evaluating a Microfinance Intervention for High Risk Women in Mongolia (clinicaltrials.gov) - Mar 18, 2015
P=N/A, N=107, Completed, Sponsor: Columbia University
N=410 --> 236 Active, not recruiting --> Completed